| Recruiting | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910 | Institut Pasteur du Cambodge | — |
| Completed | Phase 3 Single Arm, Open Study on vYF in Adults NCT07222059 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Not Yet Recruiting | Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months NCT06815835 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |
| Not Yet Recruiting | Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination NCT05450770 | ANRS, Emerging Infectious Diseases | N/A |
| Completed | A Pilot Study to Finetune Skin Processing Procedures in Recent Vaccinees, Prior to GeKoSkimm Study Initiation NCT06539351 | Institute of Tropical Medicine, Belgium | N/A |
| Recruiting | A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow F NCT06998004 | AstriVax Therapeutics | Phase 1 |
| Recruiting | Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination NCT05859490 | Oregon Health and Science University | Phase 1 / Phase 2 |
| Completed | A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL NCT05421611 | Serum Institute of India Pvt. Ltd. | Phase 3 |
| Unknown | Yellow Fever Human Infection Model With YF-17D NCT05901454 | Leiden University Medical Center | N/A |
| Active Not Recruiting | Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in Argentin NCT05644145 | Ministry of Public Health, Argentina | N/A |
| Unknown | An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity NCT05568953 | Singapore General Hospital | Phase 2 |
| Unknown | A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants NCT05447377 | Serum Institute of India Pvt. Ltd. | Phase 3 |
| Unknown | Booster Vaccine for Yellow Fever NCT05332197 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Trial of an Inactivated Yellow Fever Virus Vaccine NCT05172544 | Najit Technologies, Inc. | Phase 1 |
| Completed | Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection NCT04267809 | Singapore General Hospital | Phase 2 |
| Active Not Recruiting | Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia NCT05011123 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Active Not Recruiting | Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA NCT04942210 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Unknown | Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC NCT04235361 | University of Stirling | — |
| Completed | The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow NCT04269265 | University of Minnesota | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID NCT03891420 | BioCryst Pharmaceuticals | Phase 1 |
| Completed | Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine NCT04059471 | University of Oxford | Phase 4 |
| Completed | Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine NCT01290055 | Sri Edupuganti | Phase 4 |
| Completed | Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Chi NCT03725618 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | Evaluation of an Infant Immunization Encouragement Program in Nigeria NCT03870061 | GiveWell | N/A |
| Completed | Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea NCT03541694 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) NCT02991495 | Epicentre | Phase 4 |
| Completed | Yellow Fever Vaccine on Statin/ Non Statin Subjects NCT03116802 | Singapore General Hospital | Phase 2 |
| Completed | A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Wit NCT02743455 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children NCT02990182 | Oswaldo Cruz Foundation | — |
| Completed | Immunity After Two Doses of Yellow Fever Vaccine NCT02572518 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | — |
| Completed | The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans NCT01943305 | Singapore General Hospital | Phase 2 |
| Completed | Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vacc NCT01488890 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines W NCT01466387 | Novartis | Phase 3 |
| Completed | Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers NCT01436396 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Imm NCT01426243 | French National Agency for Research on AIDS and Viral Hepatitis | Phase 3 |
| Completed | Trial of Yellow Fever Inactivated Vaccine NCT00995865 | GE Healthcare | Phase 1 |
| Completed | Human Immune Responses to Yellow Fever Vaccination NCT00694655 | Emory University | Phase 4 |
| Completed | Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults NCT00616356 | Rockefeller University | — |
| Completed | Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) NCT00982137 | Sanofi | Phase 2 |